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Background: Glycosylated hemoglobin A1c (HbA1c) has been applied to identify type 2 diabetes (T2DM) in the U.S.
and European countries. It has not been used in China mainly due to lack of a standardized approach to measure
HbA1c, short of knowledge about racial-specific standard and deficiency of an optimal cut-off point.
Methods: To evaluate combination of HbA1c and fasting plasma glucose (FPG) in diagnosing T2DM in Chinese
adults, a multistage sampling cross-sectional study was conducted in Shanghai, China, in 2009. The FPG
measurement, HbA1c assay, and oral glucose tolerance test (OGTT) were performed in 6,661 Chinese adults (3057
men, 3604 women) who had no prior history of diabetes to identify the unrecognized T2DM.
Results: A total of 454 participants were identified as T2DM based on the 1999 World Health Organization (WHO)
diagnostic criteria. Of these patients, 239 were detected using an FPG≥ 7.0 mmol/l and 141 were further identified
using an HbA1c≥ 43 mmol/mol (6.1%), achieving a sensitivity of 83.7% and a specificity of 89.3% for combining use of
FPG and HbA1c. In subjects at high risk of diabetes, the combining use of FPG and HbA1c produced a higher sensitivity
and an improved positive predictive value (PPV), and had a satisfactory specificity and negative predictive value (NPV).
Conclusions: The combining use of FPG and HbA1c is a potential screening and diagnosis approach for T2DM in
Chinese adults, especially among those at high risk of the disease.
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Type 2 diabetes mellitus (T2DM) is a common disease
reflecting metabolic disorders characterized with hyper-
glycemia, which may lead to specific long-term compli-
cations affecting heart, brain, eyes, kidneys and nervous
system [1]. Currently, diagnosis of T2DM in Chinese
adults is principally according to the 1999 World Health
Organization (WHO) diagnostic criteria [2], namely, a
person can be diagnosed as T2DM when he or she has
1) a random plasma glucose ≥ 11.1 mmol/l accompanied
by typical symptoms of diabetes such as thirst and poly-
uria; or 2) a fasting plasma glucose (FPG) ≥ 7.0 mmol/l;* Correspondence: rli@scdc.sh.cn; wanghong.xu@fudan.edu.cn
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reproduction in any medium, provided the oror 3) a 2-hour plasma glucose (2hPG) after an oral glu-
cose tolerance test (OGTT) ≥ 11.1 mmol/l [3]. These
diagnostic criteria are determined based on the relation-
ship between glucose levels and the risk of subsequent
long-term complications.
The accuracy of glucose measurement, however, is
more or less affected by the pre-analytic instability and
biologic variability of glucose concentrations within and
between days. Moreover, OGTT requires a second blood
sample and is therefore more costly and time-consuming,
bringing inconvenient in logistics and causing uncom-
fortable feeling in individuals. Compared with 2hPG in
OGTT, FPG measurement is more reproducible and sim-
pler to perform in clinics and communities [4]. Therefore
FPG measurement is usually used alone to screen T2DM
in China [5]. Due to that a certain proportion of T2DM. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(≥ 11.1 mmol/l) [6], almost half diabetes patients remain
undiagnosed in China [7]. A more efficient and practical
method is needed to identify the individuals with dia-
betes in general population.
Hemoglobin A1c (HbA1c), a glycosylated form of
hemoglobin, reflects one’s plasma glucose levels over
past 2–3 months and is less influenced by recent diet
and emotional stress [8]. HbA1c level is a convenient and
reliable measurement of chronic glycemia [9], and can be
tested concurrently with FPG at fasting. HbA1c is associ-
ated with the risk of long-term diabetic complications
and has been used to monitor glycemic control status
in prevalent patients with diabetes for about 30 years.
Substantial studies [10-12], including one conducted
in Chinese population [12], have proved that HbA1c may
be a helpful tool for diagnosing T2DM. The American
Diabetes Association (ADA) has used an HbA1c cut-
point of 48 mmol/mol (6.5%) as one of diagnostic criteria
for T2DM in its 2010 Clinical Practice Recommenda-
tions [1].
Although HbA1c has been applied to identify T2DM in
the U.S. and European countries, it has not been used in
China, mainly due to lack of a standardized approach
to measure HbA1c, short of knowledge about racial-
specific standard and deficiency of an optimal cut-point
for detecting T2DM in the population. HbA1c values be-
tween 37 mmol/mol (5.5%) and 48 mmol/mol (6.5%)
have been associated with a substantially increased risk
for developing T2DM [13]. Due to racial disparity in
HbA1c level [14], however, the optimal threshold varies
across populations. In Chinese adults at high risk of glu-
cose intolerance, combining use of an FPG ≥ 6.1 mmol/l
and an HbA1c ≥ 43 mmol/mol (6.1%) has been shown to
predict subsequent T2DM accurately [15]. Bao et al.
[12] reported that an HbA1c ≥ 45 mmol/mol (6.3%) can
be used as a diagnostic criterion for diabetes in Chinese
adults when FPG and OGTT are not available. Given
that the HbA1c value reflects average level of glycemia
over the preceding 2–3 months and the FPG represents
the current glucose concentration, combining use of the
two indicators may improve the accuracy of diagnosis.
In this study, we included 6,661 Chinese adults with
no prior history of diabetes to evaluate whether the
combination of FPG and HbA1c can be used as a tool
for screening and diagnosis of T2DM in Chinese com-
munity settings.
Methods
Study design and population
A cross-sectional survey for T2DM was conducted in
Chinese adults in Shanghai, China, in 2009. As described
in our previous report [7], a multistage sampling process
was applied to select a representative sample of theresidents of Shanghai who were at ages of 35–74 years
old. Briefly, 4 districts and 2 counties were randomly se-
lected from all 12 districts and 7 counties. Then 1–2
sub-districts or towns were randomly selected from each
selected district or county. And then, 1–2 communities
or villages were randomly selected from each selected
sub-district or town. Finally, 1,000-2,000 eligible subjects
(permanent residents of Shanghai, 35–74 years old and
having been in the city for at least 5 years) were ran-
domly selected from each selected community or village
and invited to participate in the survey. Among 11,844
eligible adults recruited, 7,964 participated in the survey,
resulting in a response rate of 67.2%. The main reasons
for no-response were refusal to participate and absent
during the period of enrollment. Pregnant women, in-
dividuals with type 1 diabetes, and those physically or
mentally disabled were also excluded from participation.
After further excluding subjects with incomplete ques-
tionnaires and those having a prior history of T2DM
or missing values of HbA1c, we finally included 6,661
subjects (3,057 men and 3,604 women) in our analysis
(Figure 1).
The Institutional Review Board at Shanghai Municipal
Center of Disease Control and Prevention approved the
study. Informed written consent was obtained from each
participant before collecting data and bio-specimen.Data collection
Information on demographic characteristics and lifestyle
factors of the participants was collected by trained inter-
viewers. At the interview, body weight, standing height,
waist circumstance (WC) and blood pressure was mea-
sured for each participant according to a standard proto-
col, as described previously [7]. Two measurements
were taken and the mean value was used in the analyses.
Body mass index (BMI) was calculated as weight in kilo-
grams divided by the square of height in meters (kg/m2)
using direct measurements. Hypertension was defined as
the systolic/diastolic blood pressure (SBP/DBP) ≥ 140/
90 mmHg or using antihypertensive medications due to
hypertension.Laboratory measurements
All participants were asked to maintain their usual phys-
ical activities and diets for at least 3 days before having
an OGTT. After at least 10 hours of overnight fasting, a
1–1.5 ml venous blood sample was collected for each
subject in a vacuum tube containing sodium fluoride for
measuring FPG, and a 3–3.5 ml non-anticoagulated ven-
ous blood sample was drawn for measuring total choles-
terol (TC), triglycerides (TG), high and low density
lipoprotein cholesterol (HDL-C and LDL-C). For those
with an FPG < 7.0 mmol/l, a standard 75-g glucose load
Figure 1 Flow diagram of recruitment of participants.
Mo et al. BMC Endocrine Disorders 2013, 13:44 Page 3 of 8
http://www.biomedcentral.com/1472-6823/13/44was given and a second blood sample was drawn at
120 minutes after the glucose load to measure 2hPG.
Biochemical assay was conducted in several Community
Healthcare Centers according to a standardized pro-
tocol. Plasma glucose was tested using glucose oxidase-
peroxidase (GOD-PAP) method and serum cholesterol
and triglyceride levels were assayed enzymatically using
commercial reagents. HbA1c level was assayed using
high-performance liquid chromatography (HPLC), which
is recommended by the National Glycohemoglobin
Standardization Program [16]. The interassay coefficient of
variation (CV) was < 1.82% for FPG (SD < 0.23 mmol/l),
< 1.38% for TG (SD < 0.02 mmol/l), < 1.54% for TC
(SD< 0.08 mmol/l), < 1.60% for HDL-C (SD< 0.01 mmol/l),
< 5.30% for LDL-C (SD < 0.21 mmol/l), and < 6.13% for
HbA1c (SD < 0.77). An elevated WC was defined as WC ≥
90 cm for men or ≥ 80 cm for women, and an elevated TG
level referred to a fasting serum TG level of ≥
1.695 mmol/l. Hypertriglyceridemic waist (HW) pheno-
type was defined as having both an elevated WC and
an elevated TG level [17].
Statistical analysis
We used SAS version 9.1 for all statistical analyses.
Medians and interquartile ranges of demographic and
clinical characteristics of 6,661 participants were
presented and compared by sex using Wilcoxon tests.
Pearson partial correlation analysis was used to calculate
the correlation coefficient of HbA1c level with concen-
trates of FPG and 2hPG. Restricted cubic splines (RCS)
were used to evaluate the potential nonlinear relation-
ship of HbA1c with FPG or 2hPG using the 5th, 25th,75th and 95th percentiles as fixed knots. ANOVA tests
and Spearman rank correlation analyses were applied to
compare the differences and the trend of glycemic levels
among subgroups with specific demographic and clinical
characteristics. We considered P < 0.05 as statistically
significant for a two-sided test.
The 1999 WHO diagnostic criteria for T2DM were
used as the gold standard. The sensitivity was calculated
as the number of subjects correctly classified as diabetes
by a certain diagnosing threshold divided by the total
number of diabetes by the gold standard, and specifici-
ty as the ratio of true negatives to all negatives. The
Youden Index (sensitivity + specificity – 1) was used to
identify the optimal cut-off point based on ROC curve
[18]. Positive predictive value (PPV) was defined as the
number of true positives divided by the total number of
people who test positive, while negative predictive value
(NPV) referred to the proportion of subjects with a
negative test result who were correctly diagnosed.
Results
Table 1 shows the demographic and clinical characteris-
tics of participants of the survey. Compared with the
men, the women had a lower average level of BMI, WC,
SBP, DBP or TG but a higher concentration of TC,
HDL-C, LDL-C or 2hPG (all P values < 0.05). No signifi-
cant difference was observed for age and average levels
of FPG and HbA1c between men and women.
Presented in Additional file 1: Table S1 are the average
levels of FPG, 2hPG and HbA1c by demographic and
clinical characteristics of the subjects. In both sexes, the
levels of FPG, 2hPG and HbA1c increased with age and
Table 1 Demographic and clinical characteristics of the participants of the study
Characteristics Median (25th, 75th percentile) P
valueAll subjects (n = 6,661) Men (n = 3,057) Women (n = 3,604)
Age (years) 54 (48, 61) 54 (48, 61) 54 (48, 60) 0.6403
BMI (kg/m2) 24.0 (21.9, 26.3) 24.2 (22.1, 26.3) 23.9 (21.8, 26.3) 0.0315
WC (cm) 82 (76, 89) 85 (79, 90) 80 (74, 87) <0.0001
SBP (mmHg) 123 (113, 135) 125 (115, 137) 121 (111, 134) <0.0001
DBP (mmHg) 79 (72, 85) 80 (73, 87) 79 (71, 83) <0.0001
TC (mmol/l) 4.60 (4.00, 5.25) 4.45 (3.87, 5.03) 4.80 (4.14, 5.41) <0.0001
TG (mmol/l) 1.35 (0.91, 2.01) 1.40 (0.92, 2.10) 1.31 (0.90, 1.95) 0.0003
HDL-C (mmol/l) 1.30(1.10, 1.55) 1.21 (1.03, 1.45) 1.37 (1.17, 1.60) <0.0001
LDL-C (mmol/l) 2.67 (2.20, 3.09) 2.60 (2.18, 3.00) 2.71 (2.29, 3.17) <0.0001
FPG (mmol/l) 5.0 (4.6, 5.4) 5.0 (4.6, 5.4) 5.0 (4.7, 5.4) 0.0486
2hPG (mmol/l)a 6.0 (5.0, 7.1) 5.9 (4.8, 7.1) 6.0 (5.1, 7.1) <0.0001
HbA1c (mmol/mol &%) 37 (32, 40) & 5.5 (5.1, 5.8) 37 (32, 41) & 5.5 (5.1, 5.9) 37 (33, 40) & 5.5 (5.2, 5.8) 0.4235
aFor 6,422 participants who had an OGTT (2,919 men and 3,503 women). All P values were from Wilcoxon rank sum tests.
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varying from 0.10 to 0.25 (all P < 0.05). The participants
with elevated WC, hypertension, elevated TG, reduced
HDL-C or HW phenotype had a higher concentration of
FPG, 2hPG or HbA1c than those without (P < 0.05), but
with the difference in the FPG level between subjects
with and without reduced HDL-C reaching significant
only among women.
In this population, HbA1c was closely correlated with
FPG (r = 0.613, P < 0.0001) and 2hPG (r = 0.299, P <
0.0001) after adjusting for age and sex. As shown in
Figure 2, however, nonlinear does-response relationship
was observed for HbA1c level with the levels of FPG and
2hPG after accounting for age and sex (P values for
non-linear association < 0.0001).
Using the 1999 WHO diagnostic criteria as the gold
standard, the sensitivity of FPG ≥ 7.0 mmol/l in diagnos-
ing T2DM was 52.6%, while the sensitivity and specifi-
city of HbA1c of 43 mmol/mol (6.1%), the optimal
cut-point of the index in this population, reached 75.6%
and 89.3%, respectively (Table 2). The optimal threshold
of HbA1c for detecting T2DM ranged from 40 to 45
mmol/mol (5.8-6.3%) in the subgroups stratified by sex,
age, BMI, WC, TG, HDL-C or presence of hypertension
or HW phenotype. These cut-points increased with age
and appeared higher in subjects with an elevated TG level
or HW phenotype. All the optimal cut-points performed
better in sensitivity than did the FPG ≥ 7.0 mmol/l. It is of
note that the PPV of the optimal threshold increased with
age and increasing BMI, and was higher in the subjects
with elevated WC, hypertension, elevated TG, reduced
HDL-C or HW phenotype (Table 2).
As shown in Additional file 2: Table S2, 239 T2DM
were identified by elevated FPG (≥ 7.0 mmol/l) and 215by increased 2hPG (≥ 11.0 mmol/l). Of the two groups of
diabetes patients, 74.1% (177 of 239) and 45.6% (98 of
215) were identified as patients using an HbA1c cut-point
of 48 mmol/mol (6.5%) recommended by ADA, producing
a sensitivity of 60.6% and a specificity of 96.2%. By using
an HbA1c of 45 mmol/mol (6.3%) recommended by Bao
et al. for Chinese adults [12], the sensitivity increased to
67.2% and the specificity decreased to 94.0%. HbA1c of
43 mmol/mol (6.1%) achieved a sensitivity of 75.6%, a spe-
cificity of 89.3%, a PPV of 34.1% and an NPV of 98.0% in
diagnosis of T2DM.
As presented in Table 3, combining use of an FPG ≥
7.0 mmol/l and an HbA1c ≥ 43 mmol/mol (6.1%) had a
higher sensitivity (83.7%) and PPV (36.4%) than using
either one of the indicators alone in identify T2DM, to-
gether with a specificity of 89.3% and an NPV of 98.0%.
Combining use of FPG and HbA1c performed much bet-
ter among the subjects with an elevated TG level or HW
phenotype in the sensitivity (87.4% and 86.6% versus
83.7%) and PPV (42.7% and 44.9% versus 36.4%) than in
all subjects, but with a certain decrease in the specificity
(85.1% and 82.9% versus 89.3%) and NPV (98.2% and
97.4% versus 98.7%). Combining use of the two indica-
tors was observed to classify 26.9% (272/1011) of pre-
diabetes defined by 1999 WHO criteria as diabetes
(Additional file 3: Table S3).
Discussion
In this study including 6,661 Chinese adults randomly
selected from a community setting, we find that an
HbA1c threshold of 43 mmol/mol (6.1%) performs best
in diagnosing T2DM when combining with an FPG ≥
7.0 mmol/l, particularly among those at a high risk of
T2DM. Our results provide additional evidence on the
FPG (mmol/l)
Estimation --- Upper Confidence Limit ---Lower Confidence Limit … Knots
P for overall significance < 0.0001, P for linearity = 0.70 and P for nonlinearity < 0.0001
2hPG (mmol/l)
Estimation --- Upper Confidence Limit ---Lower Confidence Limit … Knots
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Figure 2 Nonlinear relationship of HbA1c with FPG and 2hPG using RCS with 4 knots.
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tients in Chinese population.
For diabetes patients, it is diabetic complications occurred
subsequently that damage their health and quality of life.
The value of OGTT in diagnosing diabetes lies in the close
relationship of 2hPG with the risk of diabetic complications.
Elevated HbA1c level has also been linked to a higher risk
of diabetic retinopathy [19], nephropathy [20], cardiovas-
cular diseases [21,22] and premature death [23,24]. More-
over, HbA1c possesses much lower intra-individual CV
(3.6%) than 2hPG (16.7%) and FPG (5.7%), and has been
used as the most reproducible and repeatable measure-
ment of glycemic status [25]. Therefore, HbA1c has great
potential as a screening or diagnosing tool for T2DM.Several cross-sectional [11,12] and prospective [10,26]
studies have provided evidence on the superior per-
formance of HbA1c to FPG in screening or diagnosing
T2DM. Consistent with these reports, we find that the
optimal HbA1c threshold of 43 mmol/mol (6.1%) had a
higher sensitivity (75.6%) than did the FPG ≥7.0 mmol/l
(52.6%) in our population, and produced a specificity of
89.3%, a PPV of 34.1% and an NPV of 98.0%. It is of
note that, in this population, the HbA1c cut-point of
45 mmol/mol (6.3%) achieved a slightly higher sensitiv-
ity (67.2% vs. 62.8%) and a slightly lower specificity
(94.0% vs. 96.1%) than in Bao et al’s report [12]. The
older average age of our population may partly explain
the difference.









Performance of optimal HbA1c value (%)
Sensitivity Specificity PPV NPV
All subjects 52.6 43 (6.1) 75.6 89.3 34.1 98.0
Gender
Male 59.0 43 (6.1) 78.2 88.8 36.7 98.0
Female 45.9 43 (6.1) 72.7 89.8 31.6 98.1
Age
35-44 68.8 40 (5.8) 84.4 84.9 15.1 99.4
45-54 59.9 41 (5.9) 85.9 82.5 23.5 98.9
55-64 51.1 42 (6.0) 82.2 81.3 27.3 98.2
65-74 40.0 45 (6.3) 70.0 91.9 51.1 96.2
BMI
≤23.0 52.9 43 (6.1) 73.6 92.7 27.0 99.0
23.1-24.9 58.0 43 (6.1) 75.0 90.1 32.9 98.2
≥25.0 50.6 43 (6.1) 76.4 85.3 37.8 96.9
Elevated WCa
No 56.6 43 (6.1) 78.9 91.8 30.2 99.0
Yes 50.4 43 (6.1) 73.6 85.8 37.1 96.6
Hypertensionb
No 52.6 43 (6.1) 76.3 90.6 29.7 98.7
Yes 52.7 43 (6.1) 74.6 84.5 42.1 95.7
Elevated TGc
No 50.8 41 (5.9) 83.2 83.1 18.3 99.1
Yes 53.9 43 (6.1) 78.1 85.1 39.9 96.8
Reduced HDL-Cd
No 56.7 43 (6.1) 72.7 89.6 31.6 98.0
Yes 46.4 43 (6.1) 79.9 88.7 38.4 98.0
HW phenotypee
No 53.2 43 (6.1) 75.3 90.8 30.0 98.6
Yes 51.9 43 (6.1) 75.9 82.9 42.3 95.4
aWC ≥ 90 cm in men and ≥ 80 cm in women;
bSBP/DBP ≥ 140/90 mmHg or being on antihypertensive medications;
cTG ≥ 1.695 mmol/l;
dHDL-C < 1.036 mmol/l (men) and < 1.295 mmol/l (women);
ehypertriglyceridemic waist phenotype, defined as having both a high WC ( ≥ 90 cm for men, ≥ 80 cm for women) and an elevated TG level ( ≥ 1.695 mmol/l).
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mmol/mol (6.1%) for HbA1c and 7.0 mmol/l for FPG,
the sensitivity and the PPV increased to 83.7% and
36.4%, respectively, with the specificity and the NPV as
high as by using HbA1c alone. Based on these results
and the fact that HbA1c is more stable and convenient
than OGTT in practice [12], we recommend that the
combination of an HbA1c ≥ 43 mmol/mol (6.1%) and an
FPG ≥ 7.0 mmol/l can be used as screening and diagnos-
tic criteria for T2DM in Chinese population. We also
find that, among the subjects with an elevated TG levelor with HW phenotype, the combination of an HbA1c ≥
43 mmol/mol (6.1%) and an FPG ≥ 7.0 mmol/l achieved
a satisfactory sensitivity and a greatly improved PPV, im-
plicating that the criteria are more efficient in detecting
T2DM among subgroups at high risk of T2DM.
Although it has been suggested that HbA1c alone has
potential to be used as a diagnostic criterion for T2DM
in Chinese adults [12], combining use of the measure-
ment with FPG has two additional advantages. Firstly,
genetic variants of hemoglobin (e.g. sickle cell trait, HbS
trait, HbC trait, etc.) and some medical conditions that
Table 3 Performance of FPG, 2hPG and HbA1c alone and combining use of FPG (mmol/l) and HbA1c (mmol/mol) in
diagnosing diabetes
Population Subjects Diabetes Se (%) Sp (%) PPV NPV
Individual test
By FPG alonea 6,661 239 52.6 100.0 100.0 96.7
By 2hPG aloneb 6,422 215 100.0 100.0 100.0 100.0
By HbA1c alonec 6,661 343 75.6 89.3 34.1 98.0
Combining use of FPG and HbA1c
All subjects 6,661 380 83.7 89.3 36.4 98.0
Subjects with elevated WCd 2,810 239 83.0 85.8 39.8 97.8
Subjects with elevated TGe 2,385 269 87.4 85.1 42.7 98.2
Subjects with HWf 1,320 162 86.6 82.9 45.5 97.4
aFPG ≥ 7.0 mmol/l; b2 hPG ≥ 11.1 mmol/l; cHbA1c ≥ 43 mmol/mol (6.1%);
dWC ≥ 90 cm in men, ≥ 80 cm in women; eTG ≥ 1.695 mmol/l; fhypertriglyceridemic waist
phenotype, defined as having both a high WC (≥ 90 cm for men, ≥ 80 cm for women) and an elevated TG level (≥ 1.695 mmol/l).
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cytes may affect the accuracy of HbA1c measurements [27].
Combining use of HbA1c and FPG can reduce the misdiag-
nosis of T2DM caused by using HbA1c alone. Secondly,
as HbA1c value reflects average level of blood glucose over
the preceding 2–3 months, subjects having diabetes in
3 months cannot be detected by testing HbA1c alone. Com-
bining use of HbA1c with FPG can compensate for this
weak point.
The main strength of the study is its large sample size.
However, the response rate of 67.2% arouses a concern
on the representation of the sample, and the lack of
characteristics information on the non-participants
limits our ability to evaluate the potential selection bias.
In this population, age appeared to be the most import-
ant characteristic factor linked to different optimal
HbA1c cut-off points (Table 2). The older average age of
our sample population due to non-response of the sub-
jects who refused to participate or were absent during
the enrolment period may lead to a higher cut-off point
of HbA1c for diagnosis. However, the non-inclusion of
these individuals is unlikely matter in the potential appli-
cation of the public health tool. Additionally, the bio-
chemical assays were conducted in several Community
Healthcare Centers, which may have led to inter-lab bias
in measurements of HbA1c. The unified protocol and
strict quality control process may help to release our
concerns. Moreover, although the sensitivity and specifi-
city of combining use of HbA1c and FPG were as high as
83.7% and 89.3%, respectively, false positive and negative
cannot be neglected. Finally, the high cost of HbA1c test
may limit its widespread use in China. Compared with
FPG assay, HbA1c test is much more expensive. Consid-
ering that the cost for HbA1c assay almost equals to that
for the OGTT [12,28], however, combining use of HbA1c
and FPG will not lead to an extra economic burden
comparing with the current application of 1999 WHO
diagnostic criteria.Conclusions
In conclusion, a threshold of HbA1c ≥ 43 mmol/mol
(6.1%) in combination with an FPG ≥ 7.0 mmol/l pro-
duce a satisfactory sensitivity and specificity for diagno-
sis of T2DM in our population. Our findings support
the combining use of FPG and HbA1c as a screening and
diagnosis tool of T2DM in Chinese adults, especially
among those at a high risk of the disease. Further epi-
demiological and clinical studies are warranted to valid-
ate our results.
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